Skip to main content

Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Trial Status: Active

Primary Objectives: Dose Escalation: Part A (SAR439859 monotherapy); Part C (combination of SAR439859 with palbociclib); Part F (Safety-Run-In - combination of SAR439859 with alpelisib): -To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR439859 based on the dose-limiting toxicity observance in monotherapy (Part A) and in combination with palbociclib (Part C), and to confirm the combination RD with alpelisib (Part F). Dose Expansion: Part B (SAR439859 monotherapy): -To assess antitumor activity by Objective Response Rate (ORR) at the SAR439859 recommended dose in monotherapy Dose Expansion: Part D (combination of SAR439859 with palbociclib) and Part G (combination of SAR439859 with alpelisib): -Overall safety profile of SAR439859 in combination with palbociclib or alpelisib Secondary Objectives: - Overall safety profile of SAR439859 as monotherapy (Parts A,B), in combination with palbociclib (Part C) or in combination with alpelisib (Part F) - Pharmacokinetic (PK) profile of SAR439859 as monotherapy (Parts A,B), in combination with palbociclib (Parts C,D), in combination with alpelisib (Parts F,G), and PK of palbociclib (Parts C,D) and alpelisib (Parts F,G) alone and / or with SAR439859 - Antitumor activity of SAR439859 as monotherapy (Part A), in combinations with palbociclib (Part C,D) or alpelisib (F,G), and Clinical Benefit Rate (CBR: CR, PR and SD≥24 weeks) in Parts A,B,C,D,F,G - ORR and CBR in Parts B, D and G per estrogen receptor 1 (ESR1) gene mutational status (mutant and wild type) at baseline and in treatment - Time to 1st response (CR,PR) (Part B,D,G) - Residual ER availability with [(18)F] Fluoroestradiol Positron Emission Tomography (FES PET) scan (Part A) - To assess potential induction / inhibition effect of SAR439859 on CYP3A (Part A,B)

Inclusion Criteria

  • Inclusion criteria: Parts A, B, C, D, F and G: - Patients must be postmenopausal women - Histological diagnosis of breast adenocarcinoma - Locally advanced or metastatic disease - Either primary tumor or any metastatic site to be positive for Estrogen Receptors (ER+) and negative for HER2 (HER2-) receptor - Patients previously treated with endocrine therapy for advanced disease: at least 6 months exposure to endocrine therapy (Patients with early relapse while on adjuvant endocrine therapy that was intitiated ≥24 months ago, or who relapsed < 12 months after completion of adjuvant endocrine therapy are eligible); in Part D, no more than 2 prior lines of endocrine therapy are allowed; in Parts F and G, patients must have received and progressed on Aromatase Inhibitor (AI) in combination with CDK4/6 Inhibitor as the first line (1L) treatment for advanced disease prior to receiving the study treatment, and not followed by further endocrine therapy for advanced disease before entering the study. - Patients previously treated with chemotherapy for advanced disease: no more than 3 prior chemotherapeutic regimens in Part A, and no more than 1 prior chemotherapeutic regimen in Parts B, C, D and F (including Antibody Drug Conjugates) - Measurable lesion Exclusion criteria: - Medical history or ongoing gastrointestinal disorders that could affect absorption of oral study drugs (including difficulties with swallowing capsules) - Patient with any other cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or any other cancer from which the patient has been disease free for >3 years) - Patients with known brain metastases - Treatment with anticancer agents (including investigational drugs) less than 2 weeks before first study treatment starts (less than 4 weeks if the anticancer agents were antibodies) - Prior treatment with another selective ER down-regulator (SERD), except fulvestrant with a washout of at least 6 weeks prior to the first study drug administration. No prior fulvestrant (or any other SERD)(Parts F, G). - Inadequate hematological and biochemical lab tests - Patients with Gilbert disease - Treatment with HIV-antiviral, antifungal and antioxidant agents less than 2 weeks before study treatment starts - Treatment with strong and moderate cytochrome P450 (CYP) 3A or CYP2C8 inducers within 2 weeks before first study treatment - Treatment with strong CYP3A inhibitors within 2 weeks before first study treatment starts - More than one prior advanced cyclin-dependent kinase (CDK) 4/6 inhibitor based therapy. Part F and G only: - Patients with current pneumonitis - Prior therapy with chemotherapy (Part G) and therapies that target the phosphoinositide 3-kinase (PI3K) axis: mammalian target of rapamycin (mTOR) infibitors, AKT inhibitors, PI3K inhibitors (Part F and G) - Patients with Diabetes Mellitus Type-I or uncontrolled Diabetes Mellitus Type-II - History of Severe Cutaneous Reaction (Stevens-Johnson syndrome [SJS], erythema multiforme [EM], toxic epidermal necrolysis [TEN], drug reaction with eosinophilia and systemic symptoms [DRESS]) - Ongoing jaw osteonecrosis The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Colorado

Aurora
University of Colorado Hospital
Status: ACTIVE

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: ACTIVE
Massachusetts General Hospital Cancer Center
Status: ACTIVE

New York

New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE

Pennsylvania

Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE

South Carolina

Charleston
Medical University of South Carolina
Status: COMPLETED

Texas

Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE
Contact: Marcella West Aguilar
Phone: 214-648-1479

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

Duration of the study, per patient, will include eligibility period (screening period) of up

to 4 weeks (28 days), treatment period (at least 1 cycle [28 days] of study treatment), and

end of treatment (EOT) visit after the last study treatment administration (i.e. at least 30

days post last treatment or until the patient receives another anticancer therapy, whichever

is earlier). The expected enrollment period is approximately 42 months.

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Sanofi Aventis

  • Primary ID TED14856
  • Secondary IDs NCI-2017-01882, U1111-1189-4896, 2017-000690-36
  • Clinicaltrials.gov ID NCT03284957